Show simple item record

dc.contributor.authorEren, E.
dc.contributor.authorHunt, J.F.V.
dc.contributor.authorShardell, M.
dc.date.accessioned2020-07-15T19:33:40Z
dc.date.available2020-07-15T19:33:40Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85087174414&doi=10.1002%2falz.12130&partnerID=40&md5=9a9a6cd9c09f4630ed1b75f7c59e3b6b
dc.identifier.urihttp://hdl.handle.net/10713/13315
dc.description.abstractIntroduction: Neuronal extracellular vesicle (nEV) tau and insulin signaling biomarkers may detect preclinical Alzheimer's disease and age-associated cognitive decline. Methods: This case-control study used repeated serum samples from 73 cognitively declining and 73 stable Wisconsin Registry for Alzheimer's Prevention participants (62.4 ± 6.3 years old). We immunocaptured nEVs; measured tau and insulin signaling biomarkers; and examined biomarker differences by group, their performance in group classification in training and test datasets (97, 49 individuals, respectively), and whether they predict cognitive performance change. Results: Declining compared to stable individuals showed higher baseline total, p231-, and p181-tau with older age and higher annualized change for p-IR and p-IGF-1R. Combining biomarkers classified decliners with 94% area under the curve (AUC), 86.0% sensitivity and 86.7% specificity, in training data, and 75% AUC, 71.4% sensitivity, and 77.3% specificity, in test data. Insulin biomarkers predicted cognitive performance change prospectively. Discussion: Combining nEV biomarkers can identify individuals with age-associated cognitive decline.en_US
dc.description.urihttps://doi.org/10.1002/alz.12130en_US
dc.language.isoen_USen_US
dc.publisherJohn Wiley and Sons Inc.en_US
dc.relation.ispartofAlzheimer's and Dementia
dc.subjectAlzheimer's diseaseen_US
dc.subjectblood biomarkeren_US
dc.subjectcognitive declineen_US
dc.subjectexosomesen_US
dc.subjectextracellular vesiclesen_US
dc.subjectinsulin resistanceen_US
dc.subjecttauen_US
dc.titleExtracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle ageen_US
dc.typeArticleen_US
dc.identifier.doi10.1002/alz.12130
dc.identifier.pmid32588967


This item appears in the following Collection(s)

Show simple item record